NSWRC(SH:600165) Zheng Quan Zhi Xing·2025-07-11 14:08Core Viewpoint - Ningxia Zhongke Biological Technology Co., Ltd. has signed a pre-restructuring investment agreement as part of its restructuring process initiated by the Shizuishan Intermediate People's Court, which aims to address the company's financial difficulties and facilitate its recovery [1][2]. Group 1: Pre-restructuring Process - The Shizuishan Intermediate People's Court decided to initiate pre-restructuring for Ningxia Zhongke Biological Technology Co., Ltd. and its subsidiary on May 30, 2024 [1]. - Two industrial investors submitted restructuring investment plans, with Hunan Chuantou Industrial Development Co., Ltd. identified as the main investor [2][5]. - The company has entered into a pre-restructuring investment agreement with both industrial and financial investors to facilitate the restructuring process [3][4]. Group 2: Investment Agreements - The pre-restructuring investment agreement with industrial investors allows them to gain actual control of the company upon successful completion of the restructuring [4]. - Financial investors, including several asset management firms, have also signed pre-restructuring investment agreements, contributing to the restructuring efforts [3][6]. - The agreements are essential for advancing the restructuring process and will be subject to court approval based on the restructuring plan [4][5]. Group 3: Investor Profiles - Hunan Chuantou Industrial Development Co., Ltd. was established in October 2021 with a registered capital of 50 million RMB and focuses on various consulting and technology services [6][7]. - Financial investors include companies like Kaiso (Hubei) Biotechnology Co., Ltd., National Trust Co., Ltd., and others, each with distinct operational focuses and financial backgrounds [8][12][13]. - National Trust Co., Ltd. manages assets totaling approximately 243.39 billion RMB and reported a net profit of 385 million RMB in 2024 [12].